UK-based Creabilis Ltd, which is developing a topical treatment for chronic pruritus, has appointed Catherine Moukheibir as the chair of its board of directors. Ms Moukheibir is an experienced investment banker as well as a biotechnology company executive.
After an initial career in consulting and banking, she moved into biotech management serving as chief financial officer at Movetis, a company that was acquired by Shire Plc in 2010. She is currently a non-executive board member of Ablynx NV and Zealand Pharma A/S and a member of the management board of Innate Pharma SA.
Ms Moukheibir holds a Master of Business Administration (MBA) degree from Yale University in the US.
Creabilis announced the appointment on 1 June 2015.
Copyright 2015 Evernow Publishing Ltd